ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Few less Shares and $$

<< Previous

Bullboard Posts

Next >>

Post by Mole101on Mar 01, 2022 3:14pm

170 Views

Post# 34472316

Few less Shares and $$

2022-03-0107:06 2022-03-01	$PMN	Williams, Eugene Warren 4 - Director of Issuer Direct Ownership	Warrants 52 - Expiration of options	$-34,500 -172,500vol $0.20 each	473,939
2022-03-0107:05 2022-03-01	$PMN	Goldstein, Elliot Paul 4 - Director of Issuer Direct Ownership	Warrants 55 - Expiration of warrants	$-34,500 -172,500vol $0.20 each	473,939
2022-03-0107:02 2022-03-01	$PMN	Geffken, Daniel 5 - Senior Officer of Issuer Direct Ownership	Warrants 55 - Expiration of warrants	$-22,613.80 -113,069vol $0.20 each	62,500